These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25712313)

  • 21. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
    He W; Kaniga K; Lynch AS; Flamm RK; Davies TA
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):417-9. PubMed ID: 22995366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imipenem/Cilastatin/Relebactam Alone and in Combination against
    Chen IH; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33139283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an
    Rico Caballero V; Almarzoky Abuhussain S; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.
    Tängdén T; Karvanen M; Friberg LE; Odenholt I; Cars O
    Infect Dis (Lond); 2017 Jul; 49(7):521-527. PubMed ID: 28264618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
    Pankuch GA; Seifert H; Appelbaum PC
    Diagn Microbiol Infect Dis; 2010 Jun; 67(2):191-7. PubMed ID: 20338710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
    Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
    Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB
    J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.
    Lin YW; Yu HH; Zhao J; Han ML; Zhu Y; Akter J; Wickremasinghe H; Walpola H; Wirth V; Rao GG; Forrest A; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.
    Córdoba J; Coronado-Álvarez NM; Parra D; Parra-Ruiz J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7316-9. PubMed ID: 26369956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
    Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y
    J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Searching for new strategies against biofilm infections: Colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus single- and double-species biofilms.
    Jorge P; Grzywacz D; Kamysz W; Lourenço A; Pereira MO
    PLoS One; 2017; 12(3):e0174654. PubMed ID: 28355248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.